What happens if a company misses a milestone tied to a later tranche?

Missing a milestone typically triggers a renegotiation of the tranche terms rather than an automatic loss of the capital, but investors may use a missed milestone as leverage to demand a lower valuation, additional protective provisions, or a step-down in the amount committed for that tranche. Because this renegotiation happens exactly when the company is most in need of cash and has the least leverage, founders should negotiate clear cure provisions and interim milestone checkpoints upfront rather than accepting a single all-or-nothing trigger.

How do milestone-based tranches differ from a simple staged term sheet closing?

A tranched financing is a specific structure within the broader term sheet in which investors commit a total amount of capital upfront but release it in installments only as specific clinical, regulatory, or commercial milestones are achieved, sharing development risk with the company rather than funding the entire amount at closing. This differs from simply closing a round in stages for administrative reasons, since a true milestone tranche makes subsequent funding conditional on performance, not just on the passage of time or completion of paperwork.

Why are milestone tranches particularly common in MedTech financings compared to other sectors?

MedTech development involves binary, high-cost risk events, such as pivotal trial outcomes, FDA clearance or approval decisions, and reimbursement determinations, that materially change the company's valuation and risk profile almost overnight, making investors reluctant to commit all capital before those events resolve. Tranching capital against these specific milestones lets investors deploy funds progressively as risk is retired, which is less common in software or consumer sectors where risk resolves more gradually rather than at discrete regulatory or clinical checkpoints.

All terms

Investment & FinanceStartup Lifecycle

Milestone-Based Tranche

Investment paid in installments triggered by predefined milestones.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

A tranched financing releases capital in stages, with later tranches conditioned on the company achieving specific clinical, regulatory, or commercial milestones - for example, IDE approval, first-patient-in, 510(k) clearance, or first commercial sale. Milestones should be objective and verifiable, with clear dates and evidence of achievement. Investors may waive a missed milestone or decline to fund the next tranche. Because later tranches are priced at the first close, achieving milestones can mean raising money at a price below the company's new value.

What the regulation says

Milestone-based tranches are contractual funding arrangements, not a distinct regulatory financing category. In the United States, Section 17(a) of the Securities Act of 1933 (enacted May 27, 1933) prohibits fraud in securities offers and sales, including exempt offerings. Descriptions of available capital, funding conditions and regulatory progress must not be materially misleading. A conditional tranche should not be presented as unconditional funding. Achieving a regulatory milestone does not independently compel investment: funding obligations, verification procedures and waiver rights depend on the financing agreement. For MedTech milestones, distinguish investigational permission from market access. Sections 520(g) and 510(k) of the Federal Food, Drug, and Cosmetic Act, added by the Medical Device Amendments of 1976 (enacted May 28, 1976), establish investigational-device and premarket-notification frameworks. IDE approval is not marketing authorization, and 510(k) clearance should not be described as FDA approval. In the EU, Regulation (EU) 2017/745 (adopted April 5, 2017; generally applicable May 26, 2021), Articles 20 and 52, addresses CE marking and conformity assessment. Agreements should identify the precise regulatory event and documentary evidence required, rather than use an ambiguous milestone such as regulatory approval.

What this means in practice

Common in MedTech where binary risk events (FDA decisions, pivotal trial readouts) make staged capital deployment attractive to investors. Founders should negotiate milestones that are objectively measurable and within the company's control.

Examples

A startup developing a novel diagnostic device secures an initial seed round, with subsequent funding tranches contingent on receiving FDA 510(k) clearance and successfully completing a pilot clinical study.
An investor commits to a Series A round for a MedTech company, releasing half the capital upfront and the remainder upon achieving the first-patient-in milestone for their pivotal clinical trial.
A venture capital firm structures its investment in a surgical robotics company such that the final tranche is disbursed only after the company secures its first commercial sale in a major market and reaches a pre-defined production volume.

Common pitfalls

•Accepting milestones that depend on third parties (FDA timelines, payer decisions) without clear cure provisions.

Frequently asked questions

A well-structured milestone is objectively measurable, verifiable by both parties without extensive dispute, and substantially within the company's own control, such as completing enrollment in a specific trial phase or submitting a regulatory filing, rather than depending entirely on a third party's timeline or decision. Milestones that hinge on FDA clearance dates or payer coverage decisions are riskier to negotiate because the company can do everything right and still miss the tranche trigger due to external delays, so founders should push for cure periods or partial releases tied to interim progress markers.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Investment & Finance

Runway

Months of operating cash a company has before running out.

Investment & Finance

Term Sheet

Non-binding outline of the key economic and control terms of an investment.

Latest in MedTech

Sources

4 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 3

Link health: 4 verified· last checked 2026-06-20· added official documents checked 2026-11-01

SVB·2NVCA·1European Innovation Council·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Investment & Finance0 / 47

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Investment & Finance
Sources: 4
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Investment paid in installments triggered by predefined milestones.

·Common in MedTech where binary risk events (FDA decisions, pivotal trial readouts) make staged capital deployment attractive to investors.
·Founders should negotiate milestones that are objectively measurable and within the company's control.
·Milestones should be objective and verifiable, with clear dates and evidence of achievement.

Remember this

Watch out: Accepting milestones that depend on third parties (FDA timelines, payer decisions) without clear cure provisions.

Related terms

You may also need

Auto-suggested from Investment & Finance and shared keywords.

All Investment & Finance terms